We are live on ! Find out more
TGTX icon

TG Therapeutics
TGTX

146 hedge funds and large institutions have $639M invested in TG Therapeutics in 2020 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 46 increasing their positions, 45 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

384% more call options, than puts

Call options by funds: $40.5M | Put options by funds: $8.37M

70% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 20

8% more funds holding

Funds holding: 135 → 146 (+11)

2% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 45

0.83% more ownership

Funds ownership: 58.45% → 59.28% (+0.83%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less capital invested

Capital invested by funds: $646M → $639M (-$6.74M)

Holders
146
Holders Change
+11
Holders Change %
+8.15%
% of All Funds
3.22%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
34
Increased
46
Reduced
45
Closed
20
Calls
$40.5M
Puts
$8.37M
Net Calls
+$32.1M
Net Calls Change
+$4.48M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$98.1M
2
EP
Eversept Partners
New York
+$21.3M
3
MP
Mangrove Partners
Connecticut
+$15.7M
4
Citadel Advisors
Citadel Advisors
Florida
+$15.1M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$11.9M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$36.4M
2
Millennium Management
Millennium Management
New York
-$25.4M
3
BM
Bridger Management
New York
-$13.4M
4
Renaissance Technologies
Renaissance Technologies
New York
-$8.43M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$7.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
TSS
151
Two Sigma Securities
New York
– -$440K -39,675 Closed
AC
152
Athanor Capital
New York
– -$367K -33,100 Closed
PP
153
PDT Partners
New York
– -$317K -28,596 Closed
Qube Research & Technologies (QRT)
154
Qube Research & Technologies (QRT)
United Kingdom
– -$256K -23,095 Closed
Walleye Trading
155
Walleye Trading
New York
– -$154K -13,900 Closed
ProShare Advisors
156
ProShare Advisors
Maryland
– -$130K -11,682 Closed
Bank of Montreal
157
Bank of Montreal
Ontario, Canada
– -$128K -11,547 Closed
9WM
158
9258 Wealth Management
Ohio
– -$122K -11,000 Closed
Ohio Public Employees Retirement System (OPERS)
159
Ohio Public Employees Retirement System (OPERS)
Ohio
– -$97K -8,700 Closed
HSBC Holdings
160
HSBC Holdings
United Kingdom
– -$98K -8,691 Closed
AF
161
Advisornet Financial
Minnesota
– -$33K -3,000 Closed
Parallax Volatility Advisers
162
Parallax Volatility Advisers
California
– -$12K -1,107 Closed
TRCT
163
Tower Research Capital (TRC)
New York
– -$1K -100 Closed
DWM
164
Darwin Wealth Management
Florida
– +$1.26K +100 New
3 4 5 6
7

TGTX Hedge Fund Activity: Q1 2020 in Review

146 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q1 2020, worth a combined $639M — down 1% from $646M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new TGTX positions and 20 closed out — a net gain of 14 holders — while 46 added to existing stakes and 45 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $98.1M. The largest seller was Great Point Partners, cutting an estimated $36.4M.

  • 146 institutional investors held TG Therapeutics (TGTX) as of Q1 2020, up from 135 in Q4 2019.
  • Funds reported $639M of TG Therapeutics stock for Q1 2020, down 1% quarter-over-quarter.
  • 34 funds opened new TG Therapeutics positions in Q1 2020 and 20 closed out, a net change of +14 holders.
  • The largest TG Therapeutics buyer in Q1 2020 was Fidelity Investments, an estimated $98.1M added.
  • The largest TG Therapeutics seller in Q1 2020 was Great Point Partners, an estimated $36.4M sold.

Based on aggregated 13F filings for Q1 2020.